基本情報
- 所属
- 自治医科大学 医学部外科学講座 消化器一般移植外科学部門 学内准教授
- 学位
- 医学博士(2008年3月 熊本大学)
- J-GLOBAL ID
- 200901014963649168
- researchmap会員ID
- 5000094045
経歴
2-
2019年9月 - 現在
-
2010年4月 - 2019年8月
学歴
2-
2005年4月 - 2008年3月
-
1993年4月 - 1999年3月
論文
32-
日本臨床外科学会雑誌 82(2) 344-349 2021年2月症例は67歳,女性.乳癌検診異常で受診した.左乳房に低エコー腫瘤を認め,針生検の結果,腺様嚢胞癌が疑われた.左乳房温存術およびセンチネルリンパ節生検を施行し,病理組織学的診断はpT1N0M0 StageIA,腺様嚢胞癌(ER-,PgR-,HER2-,Ki-67 5%)であった.補助化学療法を考慮する症例であったが,予後良好と考えられたため,化学療法は省略し放射線治療のみ施行した.術後2年6ヵ月でCTにて左肺結節を指摘されたが,原発か転移性かの鑑別が困難であったため,胸腔鏡下左肺上葉切除およびリンパ節郭清を施行した.病理組織学的診断では腺様嚢胞癌の肺転移と診断された.他の特殊型乳癌が通常の浸潤性乳管癌に準じて補助化学療法を行うことが推奨されているが,乳腺腺様嚢胞癌は多くがtriple negative症例にも関わらず予後良好と言われ,腋窩リンパ節転移が陰性ならば補助化学療法は必要としないことが多い.今回,乳腺腺様嚢胞癌で術後肺転移を認めた症例を経験したので,若干の文献的考察を加え報告する.(著者抄録)
-
Gland Surgery 10(9) 2656-2662 2021年Background: In silicone breast implant (SBI)-based breast reconstructions, aesthetic outcomes are often low due to the visible upper edge of the SBI. To ameliorate this, grafting fat harvested from the SBI operative field has not been reported to date. Therefore, we aimed to develop a novel technique for fat onlay-grafting, harvested from the inframammary fold (IMF) of the reconstructed breast, and investigate its usefulness. Methods: A total of 90 patients who underwent SBI-based breast reconstruction after a simple mastectomy were included in this study. The harvested fat was recorded by weight and grafted evenly to the medial and median upper edge of the SBI on the pectoralis major muscle. We applied this technique to 30 patients (fat onlay-grafting group) and compared them with the 60 patients (no-grafting group) who did not undergo our technique using the postoperative 1-year aesthetic outcome scores of the medial and median upper edge of the SBI. Furthermore, we investigated the correlation between the weight of harvested fat and body mass index. Results: No postoperative wound complications occurred, and infection, hardened fat, and fat lysis were not found in the fat onlay-grafting group. The medial and total aesthetic outcome scores in the fat onlaygrafting group were significantly higher than those in the no-grafting group (P< 0.05). The average weight of harvested fat was 11.9 [5-32] g. The correlation between the weight of the harvested fat and body mass index was significantly positive (R2=0.7119, P< 0.05). Conclusions: Our technique made the upper edge of the SBI invisible. Further, it was simple and less invasive with safe augmentation. Therefore, we believe that this technique can contribute to better aesthetic outcomes in SBI-based breast reconstruction.
MISC
156-
日本乳癌学会総会プログラム抄録集 23回 392-392 2015年7月
-
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 29(1) 15-30 2015年2月Tumor-associated antigens (TAAs) have been identified in many malignant tumors. Within these TAAs are peptide sequences that bind major histocompatibility complex (MHC) class I and class II molecules recognized by T cells triggering antigen-specific CD8+ cytotoxic T-cell and CD4+ T-helper cell responses. Efforts to develop vaccines for breast cancer have been underway for more than 20 years, including peptide and whole inactivated tumor cell vaccines as well as antigen-loaded dendritic cell vaccines. The majority of vaccine trials have used peptides, including single-peptide and multiple-peptide formulations using either MHC class I and class II epitopes in oil-based emulsions alone or in combination with an adjuvant, such as granulocyte-macrophage colony-stimulating factor, and Toll-like receptor agonists. Preclinical research in vitro and in animal models has been aimed at improving vaccine efficacy by identifying more immunogenic peptides and combinations of peptides and adjuvants and cytokine adjuvants that induce stronger immune responses and prolong T-cell memory. Clinical studies investigating the therapeutic potential of active immunization using peptide vaccines has found no serious side effects. In this review, we examine TAA peptide-based vaccination regimens showing promise in breast cancer patients that are also being investigated in clinical trials of safety and efficacy. We also discuss the current limitations in the peptide vaccination field and areas for future development.
-
CANCER RESEARCH 74(19) 2014年10月
-
日本臨床外科学会雑誌 75(6) 1497-1500 2014年6月症例は57歳,女性.1991年12月,右乳癌にて胸筋温存乳房切除術施行.cT2N0M0 stage IIA術後病理では乳頭腺管癌.EIA法にてER(-) PgR(-)(後日,免疫染色にてER(+) PgR(+) HER2(3+)).1996年1月,再発(肝,局所).1996年3月,肝外側区域切除術+胸壁腫瘤切除術施行.1997年11月,残肝再発認め,AC+toremifeneを使用しCR.再度残肝再発認め,2002年6月よりtrastuzumab単独で使用開始しPR.その後,内分泌療法剤や化学療法剤をtrastuzumabとの併用療法・単独療法にて使用し,病勢の進行を抑えている.現在再発より17年経過しているが,外来通院可能な状態である.HER2陽性転移性乳癌に対するtrastuzumab継続療法と化学療法が,長期生存を得るために有効な治療法であると考えられた1例を経験したので報告する.(著者抄録)
講演・口頭発表等
9共同研究・競争的資金等の研究課題
3-
日本学術振興会 科学研究費助成事業 2023年6月 - 2025年3月
-
2005年 - 2007年
-
2005年 - 2007年